[go: up one dir, main page]

WO2012097084A3 - Tenomodulin (tnmd) isoforms and uses thereof - Google Patents

Tenomodulin (tnmd) isoforms and uses thereof Download PDF

Info

Publication number
WO2012097084A3
WO2012097084A3 PCT/US2012/020969 US2012020969W WO2012097084A3 WO 2012097084 A3 WO2012097084 A3 WO 2012097084A3 US 2012020969 W US2012020969 W US 2012020969W WO 2012097084 A3 WO2012097084 A3 WO 2012097084A3
Authority
WO
WIPO (PCT)
Prior art keywords
tenomodulin
tnmd
isoforms
polypeptide
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/020969
Other languages
French (fr)
Other versions
WO2012097084A2 (en
Inventor
Albert Banes
Jie Qi
Mari TSUZAKI
Donald K. BYNUM
Ashley BANES
Jacob DMOCHOWSKI
Megan PATTERSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of WO2012097084A2 publication Critical patent/WO2012097084A2/en
Publication of WO2012097084A3 publication Critical patent/WO2012097084A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The presently disclosed subject matter relates to tenomodulin (TNMD) and its isoforms. Also described are diagnostic and therapeutic uses of tenomodulin (TNMD) and its isoforms, such as in connective tissues such as tendon. More particularly, provided herein are methods of detecting a tenomodulin polypeptide, methods of detecting a nucleic acid molecule that encodes a tenomodulin polypeptide, and methods of modulating the biological activity of a tenomodulin polypeptide.
PCT/US2012/020969 2011-01-11 2012-01-11 Tenomodulin (tnmd) isoforms and uses thereof Ceased WO2012097084A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161431576P 2011-01-11 2011-01-11
US61/431,576 2011-01-11

Publications (2)

Publication Number Publication Date
WO2012097084A2 WO2012097084A2 (en) 2012-07-19
WO2012097084A3 true WO2012097084A3 (en) 2012-11-15

Family

ID=46507652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/020969 Ceased WO2012097084A2 (en) 2011-01-11 2012-01-11 Tenomodulin (tnmd) isoforms and uses thereof

Country Status (1)

Country Link
WO (1) WO2012097084A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134788A1 (en) 2008-04-28 2009-11-05 Wispry, Inc. Tunable duplexing antenna and methods
US8810331B2 (en) 2010-12-10 2014-08-19 Wispry, Inc. MEMS tunable notch filter frequency automatic control loop systems and methods

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE NCBI 18 December 2006 (2006-12-18), "Tenomodulin, isoform CRA_c [Homo sapiens]", accession no. AX02808 *
DATABASE NCBI 27 December 2010 (2010-12-27), "Homo sapiens tenomodulin (TNMD), mRNA", accession no. M_022144 *
DATABASE NCBI 27 December 2010 (2010-12-27), "Tenomodulin [Homo sapiens]", accession no. P_071427 *
DATABASE NCBI 27 October 2008 (2008-10-27), "Homo sapiens tenomodulin, mRNA (cDNA clone IMAGE:4294374), with apparent retained intron", accession no. C034030 *
SHUKUNAMI, C. ET AL.: "Molecular cloning of tenomodulin, a novel chondromodulin-I related gene", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 280, no. 5, 9 February 2001 (2001-02-09), pages 1323 - 1327 *

Also Published As

Publication number Publication date
WO2012097084A2 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
CA2851316C (en) Genes and proteins for alkanoyl-coa synthesis
WO2011146518A3 (en) Pegylated c-peptide
EA201300669A1 (en) SUBSTITUTED 1-BENZYL CYCLOALKYL CARBONIC ACIDS AND THEIR APPLICATION
WO2013045707A3 (en) Biological materials related to c-met
WO2011084808A3 (en) Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
EA201590910A1 (en) PROTEINS BASED ON A STRUCTURAL FIBRONECTIN DOMAIN, CONNECTING PCSK9
EP4509189A3 (en) Anti-fcrn antibodies
PH12012502272A1 (en) Biological materials related to her3
HK1214168A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2012006014A3 (en) Multi-component pharmaceuticals for treating diabetes
EP4406612A3 (en) Anti-cd70 antibody drug conjugates
WO2012158780A3 (en) Lung cancer signature
WO2012028622A3 (en) Peptide or peptide complex binding to 2 integrin and methods and uses involving the same
WO2009151907A3 (en) Compositions and methods for using cells to treat heart tissue
CA2814652C (en) Human oncostatin m antibodies and methods of use
WO2012076985A8 (en) Granzyme b inhibitor compositions, methods and uses for promoting wound healing
WO2012083302A3 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
WO2013158664A3 (en) Use of p16 promoter for selective killing of senescent cells
WO2009112590A3 (en) Substances raising the activation threshold of immune cell
WO2011112566A3 (en) Basigin binding proteins
HK1207308A1 (en) Method of utilizing azelaic acid esters to modulate communications mediated by biological molecules
WO2010118291A3 (en) Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12734638

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12734638

Country of ref document: EP

Kind code of ref document: A2